|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Brendan Kennedy||Chairman, Pres & CEO||592,15k||6,35M||1972|
|Mr. Andrew Pucher||Chief Corp. Devel. Officer||253,99k||N/D||1983|
|Mr. Michael C. Kruteck||Chief Financial Officer||N/D||N/D||1962|
|Mr. Jon Edward Levin||Chief Operating Officer||N/D||N/D||1969|
|Ms. Dara Redler||Gen. Counsel & Corp. Sec.||N/D||N/D||N/D|
|Ms. Rita Seguin||Chief HR Officer||N/D||N/D||N/D|
|Mr. Greg Christopher||Exec. VP of Operations||N/D||N/D||N/D|
|Mr. Sascha Mielcarek||Managing Director of Europe||N/D||N/D||N/D|
|Mr. Josh Eades||Chief Science Officer||N/D||N/D||N/D|
|Mr. John Andonoff||Sr. VP of Global Medical Sales Devel.||N/D||N/D||N/D|
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, Israel, Ireland, New Zealand, South Africa, Switzerland, the United States, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
L'ISS Governance QualityScore di Tilray, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.